Acrylamide Risk Assessment

Susan Ferenc, D.V.M., Ph.D.
Meeting of the CIC, October 17, 2003,
Sacramento, CA
NSRL Risk Assessment Process

Risk Characterization is the first step: Determine Acceptable Level of Risk (ALR)
- $1 \times 10^{-5}$ or 1 in 100,000

Dose-response assessment characterized by EPA Cancer Slope Factor (CSF)
- 4.5

Exposure assessment characterized by calculation of a “No Significant Risk Level” (NSRL) level of exposure on a daily basis, for life
- $\frac{ALR}{CSF} \sim 0.2 \mu g/day$
Planned Risk Assessments on Acrylamide

- EPA review for IRIS database
- FDA quantitative risk assessment
- JECFA risk assessment for international standards
Dose-Response Assessment

- Uncertainties and Data Gaps
- Critical Research
Exposure Assessment

- Uncertainties and Data Gaps
- Critical Research
Consensus the world-over is that there is insufficient data to conduct a comprehensive risk assessment at this time.

Results from research currently underway or soon to begin will address data gaps so full risk assessments, including risk characterization, can be conducted.